Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 1638 | 2477 | 32.7 | 63% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 2832 | 2477 | HODGKINS DISEASE//HODGKIN LYMPHOMA//HODGKINS LYMPHOMA |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | HODGKINS DISEASE | Author keyword | 99 | 21% | 17% | 431 |
| 2 | HODGKIN LYMPHOMA | Author keyword | 56 | 22% | 9% | 222 |
| 3 | HODGKINS LYMPHOMA | Author keyword | 41 | 21% | 7% | 173 |
| 4 | INVOLVED NODE RADIOTHERAPY | Author keyword | 26 | 87% | 1% | 13 |
| 5 | ABVD | Author keyword | 24 | 57% | 1% | 29 |
| 6 | BRENTUXIMAB VEDOTIN | Author keyword | 20 | 44% | 1% | 35 |
| 7 | BEACOPP | Author keyword | 19 | 70% | 1% | 16 |
| 8 | ADVANCED HODGKINS DISEASE | Author keyword | 18 | 89% | 0% | 8 |
| 9 | GERMAN HODGKIN STUDY GRP | Address | 16 | 52% | 1% | 22 |
| 10 | INFRADIAPHRAGMATIC | Author keyword | 15 | 82% | 0% | 9 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | HODGKINS DISEASE | 99 | 21% | 17% | 431 | Search HODGKINS+DISEASE | Search HODGKINS+DISEASE |
| 2 | HODGKIN LYMPHOMA | 56 | 22% | 9% | 222 | Search HODGKIN+LYMPHOMA | Search HODGKIN+LYMPHOMA |
| 3 | HODGKINS LYMPHOMA | 41 | 21% | 7% | 173 | Search HODGKINS+LYMPHOMA | Search HODGKINS+LYMPHOMA |
| 4 | INVOLVED NODE RADIOTHERAPY | 26 | 87% | 1% | 13 | Search INVOLVED+NODE+RADIOTHERAPY | Search INVOLVED+NODE+RADIOTHERAPY |
| 5 | ABVD | 24 | 57% | 1% | 29 | Search ABVD | Search ABVD |
| 6 | BRENTUXIMAB VEDOTIN | 20 | 44% | 1% | 35 | Search BRENTUXIMAB+VEDOTIN | Search BRENTUXIMAB+VEDOTIN |
| 7 | BEACOPP | 19 | 70% | 1% | 16 | Search BEACOPP | Search BEACOPP |
| 8 | ADVANCED HODGKINS DISEASE | 18 | 89% | 0% | 8 | Search ADVANCED+HODGKINS+DISEASE | Search ADVANCED+HODGKINS+DISEASE |
| 9 | INFRADIAPHRAGMATIC | 15 | 82% | 0% | 9 | Search INFRADIAPHRAGMATIC | Search INFRADIAPHRAGMATIC |
| 10 | INVOLVED FIELD RADIOTHERAPY | 15 | 50% | 1% | 21 | Search INVOLVED+FIELD+RADIOTHERAPY | Search INVOLVED+FIELD+RADIOTHERAPY |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MOPP | 362 | 75% | 10% | 260 |
| 2 | ABVD | 263 | 70% | 9% | 219 |
| 3 | INVOLVED FIELD RADIOTHERAPY | 143 | 54% | 7% | 185 |
| 4 | MOPP CHEMOTHERAPY | 106 | 76% | 3% | 75 |
| 5 | MOPP ABV HYBRID | 86 | 96% | 1% | 26 |
| 6 | EXTENDED FIELD RADIOTHERAPY | 84 | 80% | 2% | 52 |
| 7 | STANFORD V | 72 | 81% | 2% | 43 |
| 8 | NODE RADIOTHERAPY | 57 | 95% | 1% | 19 |
| 9 | STUDY GROUP GHSG | 36 | 56% | 2% | 44 |
| 10 | COPP ABVD | 27 | 83% | 1% | 15 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis | 2013 | 19 | 25 | 60% |
| How I treat relapsed and refractory Hodgkin lymphoma | 2011 | 29 | 91 | 81% |
| State-of-the-art therapeutics: Hodgkin's lymphoma | 2005 | 102 | 54 | 70% |
| Part II: Hodgkin's lymphoma - diagnosis and treatment | 2004 | 66 | 38 | 68% |
| Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials | 2006 | 89 | 68 | 50% |
| MEDICAL PROGRESS - HODGKINS-DISEASE | 1992 | 221 | 130 | 62% |
| Managing relapsed and refractory Hodgkin lymphoma | 2008 | 36 | 57 | 81% |
| Problems in Hodgkin's disease management | 1999 | 97 | 154 | 54% |
| Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy | 2015 | 1 | 32 | 72% |
| Hodgkin Lymphoma, Version 2.2015 | 2015 | 1 | 111 | 68% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | GERMAN HODGKIN STUDY GRP | 16 | 52% | 0.9% | 22 |
| 2 | GHSG | 8 | 70% | 0.3% | 7 |
| 3 | GERMAN HODGKINS LYMPHOMA STUDY GRP | 8 | 100% | 0.2% | 5 |
| 4 | COCHRANE HAEMATOL MALIGNANCIES GRP | 3 | 26% | 0.4% | 10 |
| 5 | IST CLIN ONCOL | 2 | 67% | 0.1% | 2 |
| 6 | YORKSHIRE CANC UNIT CLIN ONCOL | 2 | 36% | 0.2% | 4 |
| 7 | SERV RADIOTER IA ONCOL | 1 | 38% | 0.1% | 3 |
| 8 | BIOSTAT MED INFORMAT SYST | 1 | 100% | 0.1% | 2 |
| 9 | BNLI | 1 | 50% | 0.1% | 2 |
| 10 | CLIN MED ONCOL MED | 1 | 50% | 0.1% | 2 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000186918 | INTERIM PET//INTERIM PET CT//PET IMAGING ST THOMAS |
| 2 | 0.0000157654 | SECONDARY LEUKEMIA//SECOND MALIGNANT NEOPLASM//THERAPY RELATED |
| 3 | 0.0000128385 | HODGKINS DISEASE//NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA//HODGKIN LYMPHOMA |
| 4 | 0.0000084506 | FOLLICULAR LYMPHOMA//NON HODGKINS LYMPHOMA//AGGRESSIVE NON HODGKINS LYMPHOMA |
| 5 | 0.0000066104 | SOLUBLE CD30//SCD30//CD30 |
| 6 | 0.0000045144 | RADIATION INDUCED HEART DISEASE//POSTMASTECTOMY RADIOTHERAPY//CONTRALATERAL BREAST DOSE |
| 7 | 0.0000040579 | BENDAMUSTINE//TREANDA//BENDAMUSTIN |
| 8 | 0.0000039202 | FERTILITY PRESERVATION//OVARIAN TRANSPOSITION//GONADOTOXICITY |
| 9 | 0.0000031787 | REDUCED INTENSITY CONDITIONING//DONOR LYMPHOCYTE INFUSION//REDUCED INTENSITY |
| 10 | 0.0000029222 | RECORD AND VERIFY//DUMMY RUN//MAILED DOSIMETRY |